Lentiviral Vectors: How They Work and Their Uses in Gene Therapy

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Lentiviral Vectors

What is a lentiviral vector?

A lentiviral vector is a modified delivery vehicle derived from lentiviruses—a subgroup of retroviruses that includes human immunodeficiency virus type 1 (HIV-1), simian immunodeficiency virus (SIV), and feline immunodeficiency virus (FIV). In gene therapy and molecular biology research, a vector is any molecular tool used to carry foreign genetic material into a cell. Lentiviral vectors are engineered so that the disease-causing and replication-competent elements of the parent virus are removed and replaced with a therapeutic or reporter gene of interest.

The defining feature that distinguishes lentiviruses from other retroviruses is their ability to infect both dividing and non-dividing cells. This property arises because the lentiviral pre-integration complex—the protein–nucleic acid structure that enters the nucleus—is actively imported through nuclear pore complexes rather than relying on the breakdown of the nuclear envelope during mitosis. This makes lentiviral vectors particularly valuable for transducing post-mitotic cells such as neurons, macrophages, and hepatocytes, which are refractory to infection by standard retroviral vectors like those derived from murine leukemia virus (MLV).

Why use lentiviruses for gene delivery?

Several properties make lentiviruses attractive starting points for vector design. First, they integrate their genetic material into the host cell genome, producing stable, long-term expression that is passed on to daughter cells. Second, they can package relatively large genetic payloads—up to approximately 8–10 kilobases (kb)—which accommodates most therapeutic genes, including large cDNAs and some promoter–reporter constructs. Third, the viral envelope can be replaced with envelopes from other viruses, a process called pseudotyping, which alters the vector's cell tropism and enhances its stability during purification.

The safety record of lentiviral vectors has improved dramatically since their first generation in the 1990s. Modern vectors are produced using a split-genome strategy in which the genes required for vector assembly are provided on separate plasmids, making the production of replication-competent virus essentially impossible. These features have propelled lentiviral vectors to the forefront of both preclinical research and approved clinical therapies, including CAR-T cell treatments for certain leukemias and lymphomas.

Structure of a Lentiviral Vector

Envelope and pseudotyping

The outermost component of a lentiviral vector particle is the lipid envelope, a membrane derived from the producer cell during budding. Embedded within this membrane are envelope glycoproteins that mediate attachment to and fusion with target cells. In the natural HIV-1 virus, the envelope protein is a trimer of gp120–gp41 heterodimers that binds the CD4 receptor and a co-receptor (CCR5 or CXCR4) on T cells.

For vector production, the native HIV-1 envelope is almost always replaced with the envelope glycoprotein from vesicular stomatitis virus (VSV-G). This substitution, known as pseudotyping, confers several advantages. VSV-G binds to the LDL receptor, which is ubiquitously expressed across mammalian cell types, giving the vector a broad tropism. Additionally, VSV-G is far more stable than the HIV-1 envelope, allowing vectors to be concentrated by ultracentrifugation without significant loss of infectivity. Other envelopes, such as those from the measles virus or modified rabies virus, can be used to target specific cell types, but VSV-G remains the standard for most applications.

The vector genome: LTRs, packaging signal, and transgene

The lentiviral vector genome is a single-stranded RNA molecule, typically 7–9 kb in length, that carries the genetic payload. This RNA is produced from a DNA plasmid that is transfected into producer cells. The key cis-acting elements—sequences that are recognized by viral proteins—include:

• Long terminal repeats (LTRs): These sequences flank the vector genome and are divided into U3, R, and U5 regions. The U3 region contains the viral promoter and enhancer elements. In self-inactivating (SIN) vectors, most of the U3 region is deleted, which eliminates the viral promoter activity after integration and reduces the risk of activating nearby cellular genes.
• Packaging signal (Ψ): A sequence located downstream of the 5′ LTR that is specifically recognized by the viral Gag protein to direct encapsidation of the RNA genome into budding particles.
• Rev-responsive element (RRE): A sequence that binds the viral Rev protein, which is required for nuclear export of unspliced vector RNA during production.
• Central polypurine tract (cPPT): A sequence that creates a DNA flap during reverse transcription, enhancing nuclear import and transduction efficiency.
• Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE): An element added to the 3′ untranslated region of the transgene to enhance mRNA stability and expression.

The transgene cassette, containing the gene of interest and its promoter, is inserted between the 5′ and 3′ LTRs. Internal promoters can be constitutive (e.g., EF1α, CMV) or cell-type-specific (e.g., synapsin for neurons), depending on the experimental or therapeutic goal.

How Lentiviral Vectors Work: The Mechanism

From virus to vector: the infection cycle

The process by which a lentiviral vector delivers its genetic cargo into a target cell is called transduction. It recapitulates the early steps of the natural lentiviral infection cycle and proceeds through the following ordered steps:

1. Binding and entry. The VSV-G envelope glycoprotein on the vector particle binds to the LDL receptor on the target cell surface. This binding triggers receptor-mediated endocytosis, internalizing the particle into an endosome. The acidic environment of the endosome (pH ~5.5) induces a conformational change in VSV-G, promoting fusion between the viral envelope and the endosomal membrane. This fusion releases the viral core—a conical capsid shell containing the RNA genome and associated enzymes—into the cytoplasm.

1. Uncoating and reverse transcription. Once in the cytoplasm, the capsid undergoes a controlled disassembly process. Within the partially uncoated core, the viral enzyme reverse transcriptase (RT) synthesizes a double-stranded DNA copy of the RNA genome. RT is an RNA-dependent DNA polymerase that also possesses RNase H activity, which degrades the RNA template after it has been copied. The reaction requires a host tRNA primer (tRNA^Lys3 for HIV-1) and proceeds through a series of strand-transfer steps to generate a linear double-stranded DNA molecule flanked by LTRs. This process typically takes 4–8 hours in dividing cells and can be slower in non-dividing cells.

1. Nuclear import. The newly synthesized viral DNA remains associated with viral and host proteins, forming the pre-integration complex (PIC). Unlike MLV, which requires nuclear envelope breakdown during mitosis, the lentiviral PIC is actively transported into the nucleus through nuclear pore complexes. This active import is mediated by the viral integrase protein, the cPPT DNA flap, and interactions with host factors such as transportin-3 and cleavage and polyadenylation specificity factor 6 (CPSF6). This nuclear import capability is the mechanistic basis for lentiviral vectors' ability to transduce non-dividing cells.

1. Integration. Inside the nucleus, the viral integrase enzyme catalyzes the insertion of the linear viral DNA into the host cell genome. Integration is not random: lentiviruses show a strong preference for actively transcribed genes, with integration sites enriched within the body of genes (introns) rather than promoter regions. This integration establishes the transgene as a permanent part of the host cell's genetic material, ensuring stable expression and transmission to all progeny cells.

1. Expression. The integrated provirus serves as a template for host RNA polymerase II, which transcribes the transgene from either the internal promoter or, in non-SIN vectors, the 5′ LTR promoter. The resulting mRNA is spliced, exported to the cytoplasm, and translated into the protein of interest. Because the vector is self-inactivating, the LTR promoter is deleted, so expression depends entirely on the internal promoter.

Integration into the host genome

Integration is a defining feature of lentiviral vectors and the source of both their greatest strength and their most significant risk. The reaction is catalyzed by integrase, which performs two enzymatic steps: 3′-end processing, in which two nucleotides are removed from each 3′ end of the viral DNA, and strand transfer, in which the processed ends are covalently joined to a staggered cut in the host chromosomal DNA. The resulting integration intermediate contains single-stranded gaps that are repaired by host DNA repair machinery.

The site selection during integration is influenced by the interaction between integrase and the host factor LEDGF/p75 (lens epithelium-derived growth factor), which tethers the PIC to chromatin marks associated with active transcription. This targeting has important safety implications: if integration occurs near a proto-oncogene, it can dysregulate its expression and contribute to malignant transformation—a phenomenon called insertional mutagenesis.

Types of Lentiviral Vectors

First, second, and third generation vectors

Lentiviral vectors have evolved through three generations, each designed to improve safety and reduce the likelihood of generating replication-competent virus.

First-generation vectors (1996) used a packaging construct that retained the HIV-1 genome with the envelope gene deleted. This construct expressed Gag, Pol, and all accessory proteins (Vif, Vpr, Vpu, Nef) from the viral LTR promoter. The vector genome contained the full LTRs, the packaging signal, and the transgene. While functional, this design required the co-transfection of three plasmids (packaging, envelope, and transfer vector) and retained many viral accessory genes that were unnecessary for vector production.

Second-generation vectors removed the accessory genes Vif, Vpr, Vpu, and Nef from the packaging construct. These genes are dispensable for vector production in most producer cell lines (e.g., HEK293T) because the cells provide the necessary functions in trans. This deletion reduces the risk of generating replication-competent virus and simplifies the system to three plasmids: packaging (Gag-Pol), envelope (VSV-G), and transfer vector.

Third-generation vectors (the current standard) further split the packaging functions. The Gag-Pol polyprotein is expressed from one plasmid, the Rev protein from a second, and the envelope from a third, with the transfer vector as a fourth. Additionally, the 5′ LTR of the transfer vector is replaced with a heterologous promoter (typically CMV) to drive expression of the vector RNA, eliminating the need for Tat, the viral transcriptional activator. Third-generation vectors also incorporate the SIN design, in which the U3 region of the 3′ LTR is deleted. During reverse transcription, this deletion is copied to the 5′ LTR, producing a provirus with inactive LTRs.

Non-integrating lentiviral vectors

Non-integrating lentiviral vectors (NILVs) are produced by introducing mutations in the integrase gene that abolish its catalytic activity. Common mutations include the D64V substitution in the catalytic core domain, which eliminates strand transfer activity while preserving the ability of integrase to support other steps of the viral life cycle. In the absence of integration, the linear viral DNA is circularized by host DNA repair enzymes to form 1- and 2-LTR circles. These episomal circles can persist in non-dividing cells for extended periods and support transgene expression, but they are diluted out in dividing cells.

NILVs are useful for applications where transient expression is desired or where the risk of insertional mutagenesis must be minimized. Examples include vaccine development, where sustained antigen expression from an episome can elicit strong immune responses without permanent genetic modification, and gene editing approaches where transient delivery of a nuclease is preferable.

Production of Lentiviral Vectors

Packaging cells and plasmids

Lentiviral vectors are produced by transient transfection of a producer cell line, most commonly HEK293T (human embryonic kidney cells expressing the SV40 large T antigen). These cells are chosen for their high transfection efficiency, rapid growth, and ability to produce high-titer virus. The production process involves co-transfecting the packaging, envelope, and transfer plasmids into the cells using a cationic lipid reagent such as polyethyleneimine (PEI) or Lipofectamine.

A typical production protocol proceeds as follows:

1. Cell preparation. HEK293T cells are seeded at approximately 60–70% confluence in a 10 cm dish in DMEM supplemented with 10% fetal bovine serum and antibiotics. The cells should be at a low passage number (ideally below passage 20) to maintain high transfection efficiency.

1. Transfection. For a 10 cm dish, a standard ratio is 10 μg of transfer vector, 6.5 μg of packaging plasmid (psPAX2 for second-generation or pMDLg/pRRE for third-generation), and 3.5 μg of envelope plasmid (pMD2.G encoding VSV-G). The DNA is mixed with a transfection reagent in serum-free medium, incubated for 15–20 minutes at room temperature, and added dropwise to the cells.

1. Harvesting. The medium is replaced with fresh complete medium 12–16 hours after transfection. Virus-containing supernatant is harvested at 24, 48, and 72 hours post-transfection, pooled, and clarified by centrifugation at 500 × g for 5 minutes and filtration through a 0.45 μm filter to remove cellular debris.

1. Concentration. If higher titers are needed, the clarified supernatant can be concentrated by ultracentrifugation at 50,000 × g for 90–120 minutes at 4°C, or by using a polyethylene glycol (PEG) precipitation method. Ultracentrifugation typically yields a 100–1000-fold concentration, producing titers in the range of 10⁸–10⁹ transducing units per milliliter (TU/mL).

1. Titer determination. The infectious titer is measured by transducing a known number of target cells (e.g., HEK293T) with serial dilutions of the vector and quantifying the percentage of transduced cells by flow cytometry if the vector expresses a fluorescent reporter, or by quantitative PCR to detect integrated vector copies.

Safety modifications to prevent replication

The split-genome design is the primary safety feature of lentiviral vectors. Because the packaging, envelope, and transfer functions are encoded on separate plasmids, multiple recombination events would be required to regenerate a replication-competent virus. Additional safety modifications include:

• Deletion of the U3 region in SIN vectors, which eliminates the viral promoter and prevents transcription of the full-length vector RNA from the integrated provirus.
• Removal of the envelope gene from the packaging construct, so that any virus produced cannot infect new cells without a supplied envelope.
• Use of heterologous promoters (e.g., CMV) to drive vector RNA expression, eliminating the need for Tat and reducing homology with the packaging construct.
• Codon optimization of the Gag-Pol genes to reduce sequence homology with the transfer vector, further decreasing the chance of recombination.

These modifications have proven highly effective: no replication-competent lentivirus has been documented in any clinical trial using third-generation vectors.

Applications of Lentiviral Vectors

Gene therapy for inherited diseases

Lentiviral vectors have been used to deliver therapeutic genes to patients with inherited disorders affecting the hematopoietic system. The most successful example is the treatment of X-linked adrenoleukodystrophy (ALD), a severe demyelinating disease caused by mutations in the ABCD1 gene. In this approach, the patient's own hematopoietic stem cells (HSCs) are harvested, transduced ex vivo with a lentiviral vector encoding a functional ABCD1 gene, and re-infused into the patient after myeloablative conditioning. The transduced HSCs engraft in the bone marrow and give rise to myeloid cells that produce the functional ALD protein, halting the demyelination process.

A similar strategy has been applied to β-thalassemia, where a lentiviral vector encoding a modified β-globin gene is used to restore hemoglobin production in erythroid cells. Clinical trials have demonstrated sustained therapeutic hemoglobin levels in treated patients, with some achieving transfusion independence.

The ex vivo approach used in these therapies offers a key advantage: the target cells are genetically modified outside the body, allowing for rigorous quality control and the ability to assess the safety of the modified cells before reinfusion.

Lentiviral vectors in CRISPR genome editing

Lentiviral vectors are widely used to deliver CRISPR/Cas9 components for genome editing. Two delivery strategies are common:

1. Delivery of Cas9 and guide RNA (sgRNA) as DNA. The Cas9 gene and sgRNA expression cassette are cloned into a lentiviral transfer vector. After transduction, the integrated vector provides stable expression of both components, enabling sustained editing. This approach is used to generate stable knockout cell lines or to perform pooled genetic screens where each cell receives a different sgRNA.

1. Delivery of Cas9 protein and sgRNA as a ribonucleoprotein (RNP). While lentiviral vectors cannot package proteins directly, they can be used to deliver an mRNA encoding Cas9 along with an sgRNA expression cassette. This provides transient Cas9 expression, reducing off-target editing.

For CRISPR knockout experiments, lentiviral delivery of sgRNA into cells that stably express Cas9 is a standard approach. The ability to transduce non-dividing cells makes lentiviral vectors particularly useful for editing post-mitotic cells such as neurons, where other delivery methods are inefficient.

Lentiviral vectors are also used to create conditional knockout mice by delivering Cre recombinase or sgRNAs targeting floxed alleles. In these applications, the vector's stable integration ensures that the editing event is inherited by all progeny cells.

Advantages and Limitations

Advantages over other vectors

Lentiviral vectors offer several advantages compared to other gene delivery systems:

• Stable expression. Integration into the host genome ensures that the transgene is maintained through cell division, providing long-term expression. This contrasts with AAV Vector, which remains predominantly episomal and is diluted in dividing cells.
• Broad tropism. Pseudotyping with VSV-G allows transduction of nearly all mammalian cell types, including hard-to-transfect cells such as primary neurons, HSCs, and quiescent lymphocytes.
• Transduction of non-dividing cells. The active nuclear import mechanism permits transduction of post-mitotic cells, a capability not shared by MLV-based retroviral vectors.
• Large cargo capacity. With a packaging limit of approximately 8–10 kb, lentiviral vectors can accommodate larger transgenes than AAV (which is limited to ~4.7 kb) or adenoviral vectors.
• Low immunogenicity. Because lentiviral vectors are produced in human cells and do not express viral proteins after integration, they elicit minimal immune responses compared to adenoviral vectors.

Limitations and risks

The principal limitation of lentiviral vectors is the risk of insertional mutagenesis. Because integration is semi-random, there is a finite probability that the vector will integrate near a proto-oncogene and dysregulate its expression. This risk was tragically demonstrated in early retroviral gene therapy trials for X-linked severe combined immunodeficiency (SCID-X1), where insertional activation of the LMO2 oncogene led to T-cell leukemia in several patients. While lentiviral vectors have a different integration profile than MLV-based vectors (preferring gene bodies rather than promoters), the risk is not eliminated.

Other limitations include:

• Size constraint. The ~10 kb packaging limit precludes delivery of very large genes or multiple expression cassettes.
• Production complexity. Generating high-titer lentiviral vectors requires specialized expertise and equipment, and the transient transfection process is difficult to scale for large clinical trials.
• Potential for silencing. The integrated provirus can be subject to transcriptional silencing by DNA methylation and histone modifications, particularly in stem cells, leading to loss of transgene expression over time.
• Insertional mutagenesis in germ cells. Although rare, integration into germline cells could result in heritable genetic modifications, raising ethical and regulatory concerns.

Safety Considerations and Common Pitfalls

Biosafety and regulation

Lentiviral vectors are classified as biosafety level 2 (BSL-2) agents in most institutions. This classification reflects the theoretical risk of generating replication-competent virus and the potential for insertional mutagenesis. Standard precautions include:

• Performing all work in a certified biosafety cabinet.
• Using appropriate personal protective equipment, including gloves and lab coats.
• Decontaminating all waste and surfaces with 10% bleach or 70% ethanol.
• Avoiding the use of sharps and aerosol-generating procedures where possible.

Institutional biosafety committees (IBCs) typically require approval before lentiviral work can begin. The approval process involves a risk assessment that considers the vector design (generation, SIN status), the transgene, and the target cells. For clinical applications, additional regulatory oversight is provided by agencies such as the FDA in the United States and the EMA in Europe.

Common pitfalls in lentiviral experiments

Several practical issues frequently compromise lentiviral experiments:

Low titer. The most common cause of low titer is poor transfection efficiency. This can result from using high-passage HEK293T cells, which lose transfection competence over time, or from using plasmid preparations with low purity. Solutions include using low-passage cells (below passage 20), verifying plasmid quality by agarose gel electrophoresis, and optimizing the DNA-to-transfection-reagent ratio.

Cytotoxicity of VSV-G. VSV-G is toxic to producer cells when expressed at high levels. This toxicity can reduce vector yield and cause the producer cells to detach prematurely. Using lower amounts of envelope plasmid (e.g., 3.5 μg per 10 cm dish) and harvesting supernatant earlier (24–48 hours post-transfection) can mitigate this issue.

Envelope incompatibility with target cells. While VSV-G has broad tropism, some cell types are resistant to transduction. For example, certain primary hematopoietic cells express low levels of LDL receptor and require higher multiplicities of infection (MOI) or the use of alternative envelopes such as RD114 or baboon endogenous retrovirus (BaEV) envelopes.

Carryover of plasmid DNA. Transfection reagents and plasmid DNA can contaminate the harvested virus, leading to false-positive results in transduction assays. Treating the supernatant with DNase I (10 U/mL for 30 minutes at 37°C) before use can reduce this contamination.

Silencing of transgene expression. The CMV promoter is frequently silenced in stem cells and certain primary cells. Using a constitutive promoter such as EF1α or PGK, which are less susceptible to silencing, is recommended for these applications.

Recombination during production. Although rare, recombination between the packaging and transfer plasmids can generate replication-competent virus. This risk is minimized by using third-generation vectors with minimal sequence homology between plasmids. Testing the harvested virus for the presence of replication-competent lentivirus is recommended for clinical-grade production.

Summary and Key Takeaways

Lentiviral vectors are powerful tools for gene delivery that combine the natural efficiency of lentiviral infection with extensive safety engineering. Their ability to integrate into the genome of both dividing and non-dividing cells, their broad tropism, and their large cargo capacity make them indispensable in both basic research and clinical gene therapy. The development of third-generation, self-inactivating vectors has dramatically reduced the risk of replication-competent virus and insertional mutagenesis, enabling their use in approved therapies for cancer and inherited diseases.

Frequently Asked Questions

What is a lentiviral vector?

A lentiviral vector is a modified virus derived from lentiviruses such as HIV-1. It is engineered to deliver therapeutic or reporter genes into cells without causing disease. The viral genes required for replication and pathogenicity are removed and replaced with the gene of interest, while the structural and enzymatic components needed for gene delivery are provided in trans during production.

What are the types of lentiviral vectors?

Lentiviral vectors are classified by generation (first, second, or third) based on the number of plasmids used in production and the degree of viral gene deletion. Third-generation vectors are the safest and most commonly used. Vectors can also be classified as integrating or non-integrating, depending on whether the integrase enzyme is functional.

How do lentiviral vectors work?

Lentiviral vectors work by binding to the target cell surface, entering through endocytosis, and releasing their RNA genome into the cytoplasm. The RNA is reverse-transcribed into DNA, which is actively transported into the nucleus and integrated into the host cell genome. The integrated transgene is then expressed by the host cell's transcription and translation machinery.

What are lentiviral vectors used for?

Lentiviral vectors are used for gene therapy of inherited diseases (e.g., β-thalassemia, adrenoleukodystrophy), CAR-T cell therapy for cancer, delivery of CRISPR/Cas9 components for genome editing, creation of transgenic animal models, and basic research applications such as gene overexpression, knockdown, and reporter assays.

Are lentiviral vectors safe?

Modern lentiviral vectors are substantially safer than earlier generations due to the split-genome design, deletion of accessory genes, and self-inactivating LTRs. The risk of generating replication-competent virus is extremely low. However, the risk of insertional mutagenesis remains, and this risk must be carefully evaluated for each application.

What is the difference between lentiviral and retroviral vectors?

Lentiviral vectors are a subtype of retroviral vectors. The key difference is that lentiviral vectors can transduce non-dividing cells because their pre-integration complex is actively imported into the nucleus, whereas standard retroviral vectors (e.g., MLV-based) require cell division for nuclear entry. Lentiviral vectors also have a different integration site preference.

Can lentiviral vectors be used for CRISPR?

Yes, lentiviral vectors are widely used for CRISPR genome editing. They can deliver Cas9 and sgRNA expression cassettes for stable knockout generation, or deliver sgRNA into cells that already express Cas9. They are also used for pooled genetic screens and for creating conditional knockout animal models.

Key Takeaways

• Lentiviral vectors are derived from HIV-1 but are engineered to be replication-incompetent and non-pathogenic.
• They can transduce both dividing and non-dividing cells, making them uniquely versatile among viral vectors.
• The vector genome integrates into the host chromosome, providing stable, long-term transgene expression.
• Third-generation, self-inactivating vectors are the current standard, offering the highest level of safety.
• Lentiviral vectors are used in approved gene therapies, CAR-T cell therapy, and CRISPR genome editing.
• The main risk is insertional mutagenesis, which can potentially activate oncogenes.
• Production requires specialized cell lines and multi-plasmid transfection, and careful attention to titer and quality is essential for reproducible results.

Further Reading

• Milone MC, O'Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018. PubMed 29654266
• Perry C, Rayat ACME. Lentiviral Vector Bioprocessing. Viruses. 2021. PubMed 33572347
• Sakuma T, Barry MA, Ikeda Y. Lentiviral vectors: basic to translational. The Biochemical journal. 2012. PubMed 22507128
• Gutierrez-Guerrero A, Cosset FL, Verhoeyen E. Lentiviral Vector Pseudotypes: Precious Tools to Improve Gene Modification of Hematopoietic Cells for Research and Gene Therapy. Viruses. 2020. PubMed 32933033
• Andorko JI et al. Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation. Molecular therapy : the journal of the American Society of Gene Therapy. 2025. PubMed 40581818
• Coradin T et al. Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector. Molecular therapy : the journal of the American Society of Gene Therapy. 2025. PubMed 40676833

Related Topics

• Expression Vector
• Shuttle Vector

Related Clinical & Scientific Guides

• MAPK Pathway: Mechanism, Function, and Clinical Relevance
• Mammalian Cell Culture Bioreactors: A Practical Guide
• Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks